Dr Lange joined Novo Nordisk in 2002, working with growth hormone,
GLP-2 and oral anti-diabetics as first operationally and subsequently
medically responsible for several projects within Global Development.
Dr Lange worked two years in Novo Nordisk Inc., USA, from
2006-2008 in the Medical Department as senior medical director. In
2008, Dr Lange moved back to Denmark as vice president, Medical
& Science liraglutide during the submission and approval phase,
transferring in 2010 upon US approval of Victoza® to insulin
degludec in a similar position.
From 2013 to 2017, he served as corporate project vice
president for Insulin & Diabetes Outcomes and subsequently
Insulin & Devices, being responsible for the development and
approval of the Novo Nordisk insulin portfolio. In January 2018, he
was appointed senior vice president for Global Development, assuming
the overall clinical development responsibilities of the Novo
Nordisk pipeline. In March 2021, Dr Lange was appointed executive
vice president for Development.